Next 10 |
2024-04-29 08:20:32 ET More on Stoke Therapeutics Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist Stoke Therapeutics prices upsized equity offering of $125M Stoke Therapeutics announces proposed public offering worth $75M ...
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial strategy and operations for life science companies – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the ...
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein exp...
2024-04-17 00:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on ...
2024-04-04 01:12:23 ET Summary Stoke Therapeutics' stock has surged after positive data from studies of its lead drug candidate, STK-001, in children with Dravet syndrome. Dravet syndrome is a severe form of epilepsy that causes multiple seizure types and developmental disabilitie...
2024-03-28 03:22:46 ET More on Stoke Therapeutics Stoke Therapeutics announces proposed public offering worth $75M Stoke stock rockets 73% on updated epilepsy drug data Seeking Alpha’s Quant Rating on Stoke Therapeutics Read the full article on Seeki...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common s...
2024-03-27 13:57:15 ET DENVER, Colo., Mar 27, 2024 ( 247marketnews.com )- This morning’s notable listings with recent news include Treasure & Shipwreck Recovery (OTCPK: BLIS ), iBio, Inc. (NYSEAMERICAN: IBIO ), Trump Media & Technology Group (NASDAQ:...
2024-03-26 16:36:29 ET More on Stoke Therapeutics Stoke stock rockets 73% on updated epilepsy drug data TD Cowen ups Stoke to buy on updated data for epilepsy drug Seeking Alpha’s Quant Rating on Stoke Therapeutics Historical earnings data for Stoke Th...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial strategy and operations for life science companies – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the ...
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein exp...
2024-04-17 00:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...